SCYNEXIS Secures Up to $214 Million in BARDA Contract for Antifungal Development
PUBLIC · SCYXSep 25, 2026
Amount Raised
$214 Million
Round Type
Funding Round
Jersey CityBiotechnologyHealth Care
Investors
Biomedical Advanced Research And Development Authority
Description
On September 25, 2026, SCYNEXIS, Inc. entered into a BARDA Contract with the Biomedical Advanced Research and Development Authority. This contract provides potential non-dilutive funding of up to $214 million to support the development of SCY-247. Initially, approximately $18.5 million will be used to advance the drug into a Phase 2 study for invasive candidiasis
Company Information
Company
SCYNEXIS
Location
Jersey City, New Jersey, United States
About
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.
Fundz sees it the moment SCYNEXIS raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.